Saxagliptin + Metformin Tablets

Project Image
Thumb Image

Therapeutic Indication

Type 2 Diabetes Mellitus
Improves glycemic control
Adjunct to diet and exercise
+91 85919 78885

Saxagliptin + Metformin

Tablet

This fixed-dose combination includes Saxagliptin, a DPP-4 inhibitor that enhances incretin activity, and Metformin, a biguanide that reduces hepatic glucose production and improves insulin sensitivity. Together, they provide effective glycemic control in type 2 diabetes mellitus.

Speciality Endocrinology | Internal Medicine
Tags DPP-4 Inhibitor | Biguanide | Antidiabetic
Strength
  • Saxagliptin 2.5 mg + Metformin 1000 mg
  • Saxagliptin 5 mg + Metformin 500 mg
Packing Size
  • 10 Tablets

Check all Tablets Range

Click to know More

Mechanism

Saxagliptin inhibits DPP-4 enzyme, prolonging incretin activity, which increases insulin release and decreases glucagon secretion. Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity.

Pharmacokinetics

  • Saxagliptin: Hepatic metabolism via CYP3A4/5, renal excretion
  • Metformin: Not metabolized, excreted unchanged in urine
  • Half-life: Saxagliptin ~2.5 hours, Metformin ~6 hours

Side Effects

  • Nasopharyngitis
  • Headache
  • Gastrointestinal upset (nausea, diarrhea)
  • Rare: Lactic acidosis, pancreatitis

Contraindication

  • Severe renal impairment
  • Metabolic acidosis
  • Hypersensitivity to Saxagliptin or Metformin

Interaction

  • Other antidiabetic agents (risk of hypoglycemia)
  • CYP3A4/5 inhibitors may increase Saxagliptin levels
  • Alcohol increases risk of lactic acidosis with Metformin

Warning and Precautions

  • Monitor renal function regularly
  • Discontinue if pancreatitis is suspected
  • Use with caution in hepatic impairment

Dosage

As directed by the Physician.